Shield Therapeutics will welcome new Chief Financial Officer to the Group, who will be a Board member, in the beginning of the month of May 2017.
Joanne Estell will bring to Shield with more than 20 years’ experience in senior finance, strategy and M&A positions. Most recently, she was Chief Financial Officer and Company Secretary of Stadium Group Plc, an AIM-listed global manufacturer of technology led products.
Carl Sterritt, Founder and Chief Executive Officer of Shield Therapeutics, said: “Joanne has an exceptional track record and I am delighted to welcome her to Shield Therapeutics as our CFO. She brings a wealth of finance experience from listed international businesses and has strong ambitions that are aligned with ours. Having evaluated, developed and delivered corporate growth strategies, the Board and I are particularly looking forward to working closely with Joanne as she plays a pivotal role in Shield’s ongoing journey towards becoming a fully-fledged, international and commercially-focused specialty pharmaceutical business.”
Joanne Estell said: “With Feraccru now firmly on the market, Shield is delivering growing revenues and expanding its reach within existing markets as well as planning for further international expansion. By working closely with Carl and Shield’s highly experienced and driven wider team, my focus will be on effectively supporting our ambitious growth plans so we can deliver increasing value to our shareholders.”